Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Eighteen-month postoperative outcomes following implantation of second generation trabecular micro-bypass stents in patients with open-angle glaucoma not controlled by one preoperative medications

Poster Details

First Author: J. Belda SPAIN

Co Author(s):    K. Schargel                    

Abstract Details


The objective of this study by the Micro-Invasive Glaucoma Surgery (MIGS) Study Group was to evaluate decrease in IOP and medication burden and safety parameters following stand-alone implantation of second generation trabecular micro-bypass stents in patients with open-angle glaucoma (OAG) not controlled on 1 preoperative topical ocular hypotensive medication.


The MIGS Study Group is comprised of surgeons visiting from eight countries and staff surgeons in Armenia. These visiting and staff surgeons have performed surgeries at one investigational site – the S.V. Malayan Ophthalmological Center in Yerevan, Armenia.


The iStent inject (Glaukos) is a single-piece titanium stent inserted in Schlemm’s canal via ab interno implantation through a temporal corneal incision. This study enrolled 57 OAG subjects on 1 preoperative medication, medicated IOP ≥ 18 mmHg and ≤ 30 mmHg, and post-medication washout IOP ≥ 22 mmHg and ≤ 38 mmHg. Postoperative medication was prescribed for elevated IOP (e.g., > 21 mmHg) or optic nerve findings. Subjects returned at 1 day, 1 week, 1, 3, 6, 12 months and semi-annually through 60 months for evaluations of adverse events, BCVA, CD ratio, visual field, pachymetry, IOP and medication use.


Fifty-seven qualified OAG subjects underwent uncomplicated implantation of 2 iStent inject devices. Preoperative mean medicated IOP was 19.5 (SD 1.5) mmHg; IOP after washout was 24.4 (SD 1.3) mmHg. At 18 months, mean IOP on 0 medications was 14.4 (SD 2.1) mmHg, a 10 mmHg (41%) decrease from preoperative unmedicated IOP. One subject was placed on medication at M18 (IOP = 17.7 mmHg). One subject with pre-existing cataract and BCVA of 0.2 (decimal) had BCVA loss ≥ 1 line from cataract progression at Month 12, with BCVA of 0.09. Cataract surgery is pending. No other ocular adverse events were reported.


Data from this series suggest second generation ab interno stents implanted as a stand-alone procedure in OAG patients on 1 preoperative medication can enable IOP reduction to ≤ 15 mmHg without postoperative medication through 18 months.

Financial Disclosure:


Back to Poster listing